TheraRadar

Competitive Landscape by Indication

151 indications, 102,602 trials mapped

Oncology

40,168 trials
Solid Tumor (Advanced)
6434 trials 541 Ph3
Merck, Eli Lilly, Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer
2555 trials 445 Ph3
AstraZeneca, Roche, Pfizer
Non-Hodgkin Lymphoma
2547 trials 223 Ph3
Roche, Genmab, Merck
NSCLC
2462 trials 395 Ph3
AstraZeneca, Merck, Roche
ALL
1949 trials 293 Ph3
Novartis, Pfizer, AstraZeneca
Colorectal Cancer
1815 trials 247 Ph3
AstraZeneca, AbbVie, Revolution Medicines, Inc.
Prostate Cancer
1621 trials 250 Ph3
Novartis, Johnson & Johnson, AstraZeneca
AML
1269 trials 118 Ph3
AbbVie, Taiho Oncology, Inc., Kura Oncology, Inc.
Multiple Myeloma
1211 trials 143 Ph3
Johnson & Johnson, GSK, AbbVie
Pancreatic Cancer
1136 trials 106 Ph3
Revolution Medicines, Inc., AstraZeneca, Seagen, a wholly owned subsidiary of Pfizer
Melanoma
1081 trials 99 Ph3
Merck, Bristol-Myers Squibb, Novartis
Hepatocellular Carcinoma
1016 trials 146 Ph3
AstraZeneca, Roche, Akeso
Hematologic Malignancies
994 trials 86 Ph3
Johnson & Johnson, Novartis, Orca Biosystems, Inc.
Ovarian Cancer
988 trials 117 Ph3
AstraZeneca, AbbVie, Merck
Head and Neck Cancer
948 trials 78 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca, Pfizer
Lung Cancer (General)
934 trials 121 Ph3
Chongqing Precision Biotech Co., Ltd, AstraZeneca, Avistone Biotechnology Co., Ltd.
Sarcoma
900 trials 63 Ph3
Eli Lilly, Hansoh BioMedical R&D Company, Philogen S.p.A.
Bladder Cancer
833 trials 123 Ph3
Merck, AstraZeneca, Pfizer
Gastric Cancer
815 trials 120 Ph3
AstraZeneca, Astellas Pharma Global Development, Inc., Chongqing Precision Biotech Co., Ltd
MDS
719 trials 58 Ph3
Bristol-Myers Squibb, Takeda, Taiho Oncology, Inc.
Esophageal Cancer
717 trials 116 Ph3
AstraZeneca, Merck, AbbVie
Glioblastoma
637 trials 45 Ph3
Novartis, Philogen S.p.A., Telix Pharmaceuticals (Innovations) Pty Limited
Brain Tumor
628 trials 51 Ph3
Jazz Pharmaceuticals, Pfizer, InSightec
SCLC
551 trials 76 Ph3
Amgen, AstraZeneca, Boehringer Ingelheim
Renal Cell Carcinoma
547 trials 51 Ph3
Merck, Bristol-Myers Squibb, Exelixis
Triple Negative Breast Cancer
526 trials 56 Ph3
Gilead, Novartis, Eli Lilly
Squamous Cell Carcinoma
501 trials 48 Ph3
Regeneron, Ankyra Therapeutics, Inc, Alentis Therapeutics AG
Hodgkin Lymphoma
494 trials 31 Ph3
Merck, AbbVie, Sichuan Baili Pharmaceutical Co., Ltd.
Cholangiocarcinoma
473 trials 45 Ph3
AstraZeneca, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Eli Lilly
Cervical Cancer
445 trials 73 Ph3
AstraZeneca, Shanghai Bovax Biotechnology Co., Ltd., Merck
CLL
435 trials 49 Ph3
BeOne Medicines, AbbVie, Ascentage Pharma Group Inc.
Neuroendocrine Tumors
403 trials 79 Ph3
Vertex Pharmaceuticals Incorporated, Quoin Pharmaceuticals, ITM Solucin GmbH
Endometrial Cancer
370 trials 43 Ph3
AstraZeneca, Genmab, Merck
Myelofibrosis
233 trials 31 Ph3
Novartis, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Mesothelioma
219 trials 14 Ph3
Novartis, NGM Biopharmaceuticals, Inc, Seagen, a wholly owned subsidiary of Pfizer
CML
209 trials 19 Ph3
Novartis, Shenzhen TargetRx, Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Thyroid Cancer
170 trials 25 Ph3
Eli Lilly, Exelixis, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER2+ Breast Cancer
151 trials 31 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., Jazz Pharmaceuticals, Roche
HER2- Breast Cancer
143 trials 16 Ph3
AstraZeneca, BeiGene, Olema Pharmaceuticals, Inc.
Merkel Cell Carcinoma
89 trials 6 Ph3
TuHURA Biosciences, Inc., ImmunityBio, Inc., Neonc Technologies, Inc.

CNS

6,711 trials
Major Depression
1017 trials 249 Ph3
Neurocrine Biosciences, Johnson & Johnson, Neumora Therapeutics, Inc.
Alzheimer's Disease
977 trials 188 Ph3
Eli Lilly, Bristol-Myers Squibb, Roche
Multiple Sclerosis
778 trials 188 Ph3
Roche, Novartis, Sanofi
Parkinson's Disease
564 trials 80 Ph3
iRegene Therapeutics Co., Ltd., Luye Pharma Group Ltd., Roche
Schizophrenia
431 trials 117 Ph3
Neurocrine Biosciences, Luye Pharma Group Ltd., Bristol-Myers Squibb
Opioid Use Disorder
367 trials 73 Ph3
Go Medical Industries Pty Ltd, Akyso Therapeutics, LLC, Boehringer Ingelheim
ALS
356 trials 80 Ph3
Amylyx Pharmaceuticals Inc., Biogen, Novartis
Migraine
347 trials 157 Ph3
AbbVie, Pfizer, H. Lundbeck A/S
Epilepsy
295 trials 89 Ph3
UCB Biopharma SRL, Xenon Pharmaceuticals Inc., SK Life Science, Inc.
Alcohol Use Disorder
279 trials 42 Ph3
Eli Lilly, Afasci Inc, Pop Test Oncology LLC
Anxiety
263 trials 52 Ph3
VistaGen Therapeutics, Inc., Beijing Union Pharmaceutical Factory Ltd, Definium Therapeutics US, Inc.
Neuropathy
240 trials 67 Ph3
argenx, Sanofi, Takeda
Autism Spectrum Disorder
215 trials 44 Ph3
Intra-Cellular Therapies, Inc., MapLight Therapeutics, Bristol-Myers Squibb
PTSD
185 trials 37 Ph3
Oui Therapeutics, Inc., Senseye, Inc., Otsuka Medical Devices Co., Ltd. Japan
ADHD
161 trials 65 Ph3
Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc., Boehringer Ingelheim
Bipolar Disorder
130 trials 40 Ph3
Intra-Cellular Therapies, Inc., Bristol-Myers Squibb, Xenon Pharmaceuticals Inc.
Huntington's Disease
55 trials 9 Ph3
Roche, Novartis, Skyhawk Therapeutics, Inc.
OCD
51 trials 6 Ph3
Vericel Corporation, Biohaven Pharmaceuticals, Inc.

Click any indication to see full competitive landscape (all sponsors, trials, phases).

Data: ClinicalTrials.gov | Mapping: Indication Taxonomy